文献速递治疗药物监测与药物基因组学药物相互作用特殊人群用药

用茄啶来源CYP2D6表型分析揭示多药老年患者表型转化

Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients.
PubMed 文献 · Br J Clin Pharmacol · 2025-02-16

该研究在88例多药老年患者中,用饮食来源的茄啶代谢物SSDA/茄啶比值进行CYP2D6表型分析,并与基因型活性评分比较。校正协变量后,每增加一个CYP2D6底物/抑制剂,功能性变异携带者的预期活性评分降低0.53(95%CI 0.85-0.21)。

要点

  • SSDA/茄啶比值与CYP2D6基因型活性评分显著相关,可识别弱代谢者。
  • 多药老年患者中每增加一个CYP2D6底物/抑制剂,活性评分降低0.53。
  • 饮食来源生物标志物可用于揭示老年患者CYP2D6表型转化。

核心结论

  • 测量饮食来源生物标志物进行CYP2D6表型分析可揭示老年患者中的表型转化。

研究设计与样本

  • 在88例有完整用药记录的多药老年患者中,采集血样并用液相色谱-串联质谱测定茄啶及其代谢物,进行CYP2D6表型分析,同时进行基因分型并计算活性评分。

主要发现

  • 在校正年龄、性别、Charlson共病指数和估算肾小球滤过率的模型中,功能性CYP2D6变异携带者每增加一个CYP2D6底物/抑制剂,预期活性评分显著降低0.53(95%CI 0.85-0.21)分(R²=0.242)。

临床怎么用

  • 对于多药老年患者,可考虑用饮食来源的茄啶代谢物比值评估CYP2D6实际活性,辅助识别因合并用药导致的表型转化。

局限性

  • 本研究为观察性队列,样本量88例,结果需在更大样本中验证。
  • 研究基于单中心老年人群,外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Phenoconversion, a genotype-phenotype mismatch, challenges a successful implementation of personalized medicine. The aim of this study was to detect and determine phenoconversion using the solanidine metabolites 3,4-seco-solanidine-3,4-dioic acid (SSDA) and 4-OH-solanidine as diet-derived cytochrome P450 2D6 (CYP2D6) biomarkers in a geriatric, multimorbid cohort with high levels of polypharmacy. METHODS: Blood samples and data of geriatric, multimedicated patients were collected during physician counsel (CT: NCT05247814). Solanidine and its metabolites were determined via liquid chromatography/tandem mass spectrometry and used for CYP2D6 phenotyping. CYP2D6 genotyping was performed and activity scores (AS) were assigned. Complete medication intake was assessed. A shift of the AS predicted via genotyping as measured by phenotyping was calculated. RESULTS: Solanidine and its metabolites were measured in 88 patients with complete documentation of drug use. Patients had a median age of 83 years (interquartile range [IQR] 77-87) and the majority (70.5%, n = 62) were female. Patients took a median of 15 (IQR 12-17) medications. The SSDA/solanidine metabolic ratio correlated significantly with the genotyping-derived AS (P < .001) and clearly detected poor metabolizers. In the model adjusted for age, sex, Charlson Comorbidity Index and estimated glomerular filtration rate each additional CYP2D6 substrate/inhibitor significantly lowered the expected AS by 0.53 (95% confidence interval 0.85-0.21) points in patients encoding functional CYP2D6 variants (R2 = 0.242). CONCLUSIONS: Phenotyping of CYP2D6 activity by measurement of diet-derived biomarkers elucidates phenoconversion in geriatric patients. These results might serve as a prerequisite for the validation and establishment of a bedside method to measure CYP2D6 activity in multimorbid patients for successful application of personalized drug prescribing.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sarömba JA, Müller JP, Tupiec J, et al. Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. Br J Clin Pharmacol. 2025. PMID: 39957076. doi:10.1002/bcp.70004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。